Printed from Voxsanity (voxsanity.com.au) — NCT05519085 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
You have been diagnosed with multiple myeloma (a type of blood cancer) and your disease can be measured through specific blood, urine, or lab tests.
You have received between 1 and 3 previous treatments for multiple myeloma.
At least one of your previous myeloma treatments worked to some degree (your disease at least partially responded to it).
Who may not be able to join:
Your myeloma got worse during or within 60 days of finishing a specific type of treatment called a "proteasome inhibitor" — though there are some exceptions to this rule depending on which drug was used and how it was given (confirm with trial site).
If you previously had a treatment containing a drug called bortezomib, but it did not work at least partially, or you had to stop taking it because of side effects, you may not be eligible.
You have previously been treated with either mezigdomide or pomalidomide (specific myeloma drugs).
There may be additional eligibility requirements not listed here that the trial team will check.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Local Institution - 0055, Liverpool, New South Wales
Local Institution - 0004, Waratah, New South Wales
Local Institution - 0017, Wollongong, New South Wales
Local Institution - 0327, Birtinya, Queensland
Local Institution - 0221, Box Hill, Victoria
Local Institution - 0003, Melbourne, Victoria
Local Institution - 0002, Melbourne, Victoria
Local Institution - 0040, Nedlands, Western Australia
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT05519085
Sponsor: Celgene
Phase: Phase 3
Status: Recruiting
Condition: Myeloma
Trial contact: 855-907-3286
More information: https://clinicaltrials.gov/study/NCT05519085
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
You have been diagnosed with multiple myeloma (a type of blood cancer) and your disease can be measured through specific blood, urine, or lab tests.
You have received between 1 and 3 previous treatments for multiple myeloma.
At least one of your previous myeloma treatments worked to some degree (your disease at least partially responded to it).
Who may not be able to join:
Your myeloma got worse during or within 60 days of finishing a specific type of treatment called a "proteasome inhibitor" — though there are some exceptions to this rule depending on which drug was used and how it was given (confirm with trial site).
If you previously had a treatment containing a drug called bortezomib, but it did not work at least partially, or you had to stop taking it because of side effects, you may not be eligible.
You have previously been treated with either mezigdomide or pomalidomide (specific myeloma drugs).
There may be additional eligibility requirements not listed here that the trial team will check.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Celgene
Registry
ClinicalTrials.gov
Start date
20 September 2022
Est. completion
10 January 2027
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇨🇱 Chile
🇨🇳 China
🇨🇿 Czechia
🇫🇮 Finland
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇮🇳 India
🇮🇪 Ireland
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇳🇿 New Zealand
🇵🇱 Poland
🇵🇹 Portugal
Puerto Rico
🇷🇴 Romania
🇿🇦 South Africa
🇰🇷 South Korea
🇪🇸 Spain
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-free Survival (PFS)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.